Clover BioPharmaceuticals COVID-19 Vaccine Trial with Dynavax (DVAX) Adjuvant Demonstrates 79% Efficacy Against Delta Variant

Clover BioPharmaceuticals COVID-19 Vaccine Trial with Dynavax (DVAX) Adjuvant Demonstrates 79% Efficacy Against Delta Variant

Dynavax Technologies (DVAX) stock price is soaring today following exciting news regarding trials for the COVID-19 vaccine adjuvanted with Dynavax's CpG 1018 adjuvant (an “adjuvant” is an ingredient added to vaccines to increase the immune response in individuals, thus making the vaccine more effective).

According to a data report released by Dynavax’s partner, Clover Biopharmaceuticals, the vaccine candidate under study, SCB-2019 (CpG 1018/Alum), met primary and secondary efficacy endpoints during Phases 2/3 of the “SPECTRA” trial.

The trial enrolled over 30,000 participants (adult and elderly) across five different countries and four continents, making the study one of the most diverse COVID-19 vaccine trials to have been conducted.

Results from the study (which observed variants specifically)  displayed 100% efficacy against severe COVID-19 and hospitalization, and 84% efficacy against moderate-to-severe COVID-19 caused by any given strain of the virus that was observed in the study. The vaccine also displayed 79% efficacy against COVID-19 of any severity caused by the Delta variant, which has been the globally dominant variant. It also demonstrated 92% efficacy against the Gamma variant, and 59% against the Mu variant.

As always, whenever we see big news like this, we like to take a look at the Unusual Whales Flow for both the day before and the day of such news. In the case of DVAX, it would appear that investors expected some form of good news for the trials, or at the very least, are bullish long term.

Take the above image, for instance. All ask-side flow for DVAX yesterday, September 21, 2021, above $5k in premium is bullish. Although the order sizes aren’t absolutely massive, as we sometimes see, these orders do display a bullish sentiment. There was a focus on the $10 call LEAP for January 2023, which could indicate long-term expectations of upward price movement.

It will be exciting to see what else comes of this vaccine, especially given these results also displayed no new significant differences to the safety profile when compared to placebo. The data shows impressive efficacy and tolerability, which could

Today, following the news, we see a much higher influx of volume, and the sentiment remains the same.

Although there is still a tendency toward longer dated calls on DVAX, now we see more monthly orders coming in, namely those contracts expiring on 10/15/2021. Investors and traders appear to be pleased with the news (as they should be, given the data that was reported), and the DVAX stock price and Flow are both reflective of that sentiment. At the time of posting, DVAX is up 21.2% (+$3.17) to $18.03, having reached a morning high of $18.30.